Antibodies against the retrovirus envelope glycoprotein (gp70) of mouse xenotropic retrovirus, BALB virus 2 (Bv2) reacted with the adult worms of Schistosoma japonicum and S. mansoni. This reaction was completely inhibited after adsorption of the antibodies with virions of retrovirus. The reactive schistosome antigen was located in the subtegumental layer of the adult male fluke and in the vitelline gland of the adult female of S. japonicum and S. mansoni. Proteins extracted from both parasites were examined by immunoblot analysis. Anti-Bv2 gp70 antiserum reacted with those proteins from both schistosomes and the band patterns were different among sexes and species. Southern hybridization of the DNA extracted from adults of S. japonicum and S. mansoni demonstrated the presence of sequences homologous to the env gene of mouse ecotropic and xenotropic retroviruses. DNA sequences homologous to the gag and pol regions of the ecotropic murine leukaemia virus were also detected in the DNAs of schistosomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/s0031182000060996 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of schistosomiasis infection on maternal and neonatal outcomes in pregnancy: a prospective cohort study in Nigeria.
BMC Pregnancy Childbirth
December 2024
Department of Obstetrics & Gynaecology, Nnamdi Azikiwe University Teaching Hospital Nnewi, Anambra state, P.M.B 5025, Nnewi, West Africa, Nigeria.
Background: Schistosomiasis, a neglected tropical disease, affects approximately 40 million women of reproductive age contributing to preventable anaemia during pregnancy, intrauterine growth retardation and low birth weight. In spite of the high prevalence rate of this disease among school aged children in Abakaliki, no study in Abakaliki has looked at the burden of Schistosomal infection in pregnancy with a view to determining maternal and neonatal outcomes.
Objective: To determine the association between schistosomal infection and maternal anemia, low birth weight, and other neonatal outcomes in Abakaliki.
Association of current Schistosoma mansoni, Schistosoma japonicum, and Schistosoma mekongi infection status and intensity with periportal fibrosis: a systematic review and meta-analysis.
Lancet Glob Health
January 2025
Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address:
Background: Periportal fibrosis is a severe morbidity caused by both current and past exposure to intestinal schistosomes. We aimed to assess the association between current infection status and intensity of Schistosoma mansoni, Schistosoma japonicum, or Schistosoma mekongi with periportal fibrosis.
Methods: In this systematic review and meta-analysis, we searched the Cochrane Central Register of Controlled Trials, Embase, Global Health, Global Index Medicus, and MEDLINE from database inception to June 18, 2024.
Vaccine value profile for schistosomiasis.
Vaccine
July 2024
World Health Organization, Geneva, Switzerland.
Article Synopsis
- * In 2019, approximately 236.6 million people required treatment for schistosomiasis, highlighting its significant impact on fishing and agricultural communities.
- * The Vaccine Value Profile (VVP) is a comprehensive assessment created by a group of experts to evaluate the public health and economic potential of new vaccines targeting schistosomiasis, emphasizing the need to address existing research gaps.
Schistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities.
Immun Inflamm Dis
November 2024
Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, AlBeheira, Egypt.
Article Synopsis
- * The transmission of this disease requires freshwater snails and human contact with contaminated water, with no effective vaccines currently available despite ongoing research into potential candidates.
- * Praziquantel (PZQ) is a key medication for treating schistosomiasis, but its widespread use has raised concerns about drug resistance, while reinfection in high-risk areas and immature worms limit its effectiveness, highlighting the urgent need for a vaccine.
A Recent Advance in the Diagnosis, Treatment, and Vaccine Development for Human Schistosomiasis.
Trop Med Infect Dis
October 2024
Marwadi University Research Center, Department of Microbiology, Faculty of Sciences, Marwadi University, Rajkot 360003, Gujarat, India.
Article Synopsis
- * The disease is caused by several species of schistosomes and can result in two forms: intestinal and urogenital, with both involving co-infections that complicate treatment and outcomes; women are particularly at risk due to exposure to contaminated water during daily activities.
- * The primary treatment is Praziquantel, but it doesn’t prevent re-infections; ongoing research aims to improve schistosomiasis diagnosis through molecular techniques and develop vaccines, focusing on
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!